• Home
  •  / Coherus BioSciences

Coherus BioSciences

OverviewSuggest Edit

Coherus BioSciences is engaged in developing and commercializing biosimilar drugs of the highest quality and value. The Company’s product candidates include CHS-1701, drug pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma.

TypePublic
Founded2010
HQRedwood City, USMap
Websitecoherus.com
Employee Ratings4.4More
View Jobs (26)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)291(+7%)
Job Openings26
Revenue (FY, 2019)$356.1 M
Share Price (May 2020)$17.1 (+6%)

Key People/Management at Coherus BioSciences

Dennis M. Lanfear

Dennis M. Lanfear

President, CEO & Chairman
James Healy

James Healy

Director
Jean-Frederic Viret

Jean-Frederic Viret

Chief Financial Officer
V. Bryan Lawlis

V. Bryan Lawlis

Director
Peter Watler

Peter Watler

Chief Technical Officer
Vladimir Vexler

Vladimir Vexler

Chief Scientific Officer
Show more

Coherus BioSciences Office Locations

Coherus BioSciences has offices in Redwood City and Camarillo
Redwood City, US (HQ)
333 Twin Dolphin Dr #600
Camarillo, US
4014 Camino Ranchero Unit A
Show all (2)

Coherus BioSciences Financials and Metrics

Coherus BioSciences Revenue

Coherus BioSciences's revenue was reported to be $356.07 m in FY, 2019
USD

Revenue (Q1, 2020)

116.2m

Net income (Q1, 2020)

35.6m

EBIT (Q1, 2020)

40.9m

Market capitalization (22-May-2020)

1.2b

Closing stock price (22-May-2020)

17.1

Cash (31-Mar-2020)

193.3m

EV

1.2b
Coherus BioSciences's current market capitalization is $1.2 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

31.1m30.0m190.1m1.6m356.1m

Revenue growth, %

(3%)533%

General and administrative expense

17.6m36.0m51.6m71.3m94.2m137.0m

R&D expense

78.2m213.1m254.4m162.4m110.2m94.2m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

12.4m14.1m161.0k1.4m37.1m83.4m111.7m116.2m

Cost of goods sold

2.2m601.0k

Gross profit

34.9m82.8m

Gross profit Margin, %

94%99%
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

150.4m158.2m124.9m126.9m72.4m177.7m

Accounts Receivable

142.0m

Prepaid Expenses

18.4m83.0k5.0m

Inventories

1.9m1.7m9.8m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

100.9m115.1m206.1m153.7m179.6m220.9m159.7m124.9m73.4m135.6m82.0m130.0m101.2m81.5m105.9m165.1m193.3m

Accounts Receivable

2.0m1.5m540.0k1.2m419.0k419.0k26.0k46.5m77.4m89.6m167.5m

Prepaid Expenses

18.0m20.1m27.0m31.7m26.0m15.0m16.6m30.5m34.2m21.1m32.0k145.0k179.0k5.6m5.2m3.1m6.4m

Inventories

2.3m4.3m7.7m16.4m
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(87.2m)(223.9m)(127.8m)(238.3m)(209.4m)89.8m

Depreciation and Amortization

674.0k3.0m3.4m3.2m

Inventories

(5.5m)(48.2m)

Accounts Payable

3.6m(5.0m)(3.8m)(301.0k)9.9m
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(58.2m)(40.8m)(99.9m)(171.4m)(65.5m)(135.7m)(51.8m)(74.8m)(130.2m)(189.2m)(44.3m)(88.0m)(146.8m)(20.0m)3.6m50.6m35.6m

Depreciation and Amortization

439.0k232.0k632.0k1.3m717.0k1.4m2.2m865.0k1.7m2.5m922.0k1.8m2.6m691.0k1.4m2.2m607.0k

Inventories

(6.4m)(16.7m)(31.2m)(9.6m)

Accounts Payable

552.0k3.0m7.1m19.1m(6.8m)(7.4m)(1.6m)(7.3m)(3.8m)(9.2m)(1.1m)(2.3m)(7.8m)(4.0m)4.0m(1.4m)(5.0m)
show all
USDY, 2020

EV/EBIT

28.7 x

EV/CFO

86.9 x

Financial Leverage

3 x
Show all financial metrics

Coherus BioSciences Online and Social Media Presence

Coherus BioSciences's Trends

Embed Graph

Coherus BioSciences News and Updates

April 13, 2020

Coherus BioSciences Provides First Quarter 2020 Financial Update and Fiscal Year 2020 COVID-19 Impact Insights

COVID-19 Impact Anticipated to be Limited Primarily to Second Quarter 2020 COVID-19 Impact Anticipated to be Limited Primarily to Second Quarter 2020
February 26, 2020

Coherus BioSciences Management to Present at the 40th Annual Cowen Healthcare Conference

REDWOOD CITY, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 40th Annual Cowen Healthcare Conference on Tuesday, March 3, 2020 at 9:20 a.m. ET, being held in Boston.
February 06, 2020

Coherus BioSciences to Report Fourth Quarter and Full Year Financial Results on February 27th

REDWOOD CITY, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its fourth quarter and full year 2019 financial results will be released after market close on Thursday, February 27, 2020. Starting at 4:30 p.m. ET, C…
January 14, 2020

Innovent Out-Licenses Commercial Rights for Avastin® Biosimilar to Coherus BioSciences in the United States and Canada

SUZHOU, China, Jan. 13, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or the "Company") (HKEX: 01801), a biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today...
January 03, 2020

Coherus BioSciences Management to Present at the 38th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 11:00 a.m. PT, being held in San Francisco.
November 12, 2019

Coherus BioSciences Management to Present at Two Upcoming Investor Healthcare Conferences

REDWOOD CITY, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare conferences.
Show more

 Coherus BioSciences Frequently Asked Questions

  • When was Coherus BioSciences founded?

    Coherus BioSciences was founded in 2010.

  • Who are Coherus BioSciences key executives?

    Coherus BioSciences's key executives are Dennis M. Lanfear, James Healy and Jean-Frederic Viret.

  • How many employees does Coherus BioSciences have?

    Coherus BioSciences has 291 employees.

  • What is Coherus BioSciences revenue?

    Latest Coherus BioSciences annual revenue is $356.1 m.

  • What is Coherus BioSciences revenue per employee?

    Latest Coherus BioSciences revenue per employee is $1.2 m.

  • Who are Coherus BioSciences competitors?

    Competitors of Coherus BioSciences include Amgen, Rallybio and NantKwest.

  • Where is Coherus BioSciences headquarters?

    Coherus BioSciences headquarters is located at 333 Twin Dolphin Dr #600, Redwood City.

  • Where are Coherus BioSciences offices?

    Coherus BioSciences has offices in Redwood City and Camarillo.

  • How many offices does Coherus BioSciences have?

    Coherus BioSciences has 2 offices.